Ovarian cancer is three times more lethal than breast cancer and it is the leading cause of gynaecological cancer deaths in the United States. It is often diagnosed in their advanced stage that’s why researchers at the Yale School of Medicine in New haven, Conn., have developed a blood test that will detect the ovarian cancer in its early stages with 99 percent accuracy. The phase II clinical trial led by Dr. Gil Mor which showed 95 percent effectiveness used a new platform called multiplex technology to simplify the test into one single reaction using very small amount of serum from the blood. In the platform, 6 protein biomarkers were used instead of 4 to increase the specificity of the test from 95 to 99.4 percent. Previous tests have detected 15 to 20 percent of new tumors.